ViroPharma Shares Drop as Maribavir Fails Phase III

February 2009
Bioworld Week;2/16/2009, Vol. 17 Issue 7, p3
The article reports on the decline of shares of ViroPharma Inc. by 53% due to the failure of its antiviral drug maribavir to meet its primary endpoint of preventing cytomegalovirus (CMV) disease in a Phase III trial in patients undergoing stem cell transplant. It has also failed to hit secondary endpoints of decreasing the need for anti-CMV treatment.


Related Articles

  • ViroPharma Shareholder Alert: The Briscoe Law Firm and Powers Taylor, LLP Announce Investigation Into ViroPharma Inc.  // Biomedical Market Newsletter;6/1/2012, Vol. 21, p1 

    The article informs that ViroPharma Inc. is under the investigation of Willie Briscoe, founder of Briscoe Law Firm PLLC and Powers Taylor LLP for violating securities. It mentions that ViroPharma has failed to disclose the actual information related to the supplemental drug application for...

  • ViroPharma Sinks After FDA Denies Vancocin Exclusivity. Powers, Marie // BioWorld Today;4/11/2012, Vol. 23 Issue 70, p1 

    The article reports on the refusal by the U.S. Food and Drug Administration (FDA) of a supplemental new drug application for Vancocin, the antibiotic drug of ViroPharma Inc. On April 10, 2012, ViroPharma's share dropped by 21.6% in response to the FDA news. Since 2006, the firm has been fighting...

  • FDA Actions.  // Critical Care Alert;Dec2009 Pharmacology Watch, p2 

    The article reports on the approval of the Food and Drug Administration (FDA) on the use of IV antiviral peramivir for treatment of inpatients with 2009 H1N1 influenza in the U.S.

  • New molecular entities/new biologics.  // Formulary;Apr2003, Vol. 38 Issue 4, p182 

    Reports on the U.S. Food and Drug Administration's approval of enfuvirtide, an anti-HIV drug. Efficacy; Safety; Dosing; Availability; Cost.

  • FDA Encourages Combo Product Development. Wechsler, Jill // Applied Clinical Trials;Mar2005, Vol. 14 Issue 3, p28 

    Reports on the approval of a fixed-dose-combination (FDC) treatment for AIDS under a new policy by the U.S. Food and Drug Administration (FDA). Encouragement of combo product development; Modification of preclinical and clinical testing requirements; Development of antiviral FDC specifically for...

  • FDA Warnings Dominate Pharmaceutical News. Elliott, William T. // Neurology Alert;Jan2008, Vol. 26 Issue 5, p1 

    Thee article offers updates on the U.S. Food and Drug Administration (FDA). The agency and its advisory committee have issued warnings on several drugs including erythropoiesis-stimulating agents, oseltamivir and zanamivir for the treatment of influenza and rosiglitazone for the treatment of...

  • Siga files application for emergency use of antiviral drug.  // PharmaWatch: Biotechnology;May2008, Vol. 7 Issue 5, p10 

    The article reports on the submission of an application by Siga Technologies Inc. to support an emergency use authorization of its orally active, smallpox antiviral drug ST-246. The emergency use authorization mechanism enables the U.S. Food and Drug Administration (FDA) Commissioner to...

  • Enfuvirtide. Coleman, Craig I.; Musial, Bogdan L.; Ross, Jack // Formulary;Apr2003, Vol. 38 Issue 4, p204 

    Focuses on enfuvirtide, the first member of antiretrovirals to gain U.S. Food and Drug approval for the treatment of HIV-1 infection. Pharmacology; Pharmacokinetics; Clinical trials of enfuvirtide; Safety and tolerability; Drug interactions; Dosage and administration; Cost. INSET: Formulary...

  • Aurobindo gets US-FDA nod for AIDS drug.  // Chemical Business;Jul2005, Vol. 19 Issue 7, p57 

    Reports on the approval of the antiretroviral agent lamivudine developed by Aurobindo Pharma Ltd. by the U.S. Food and Drug Administration. Use of the drug in the U.S. President's Emergency Plan for AIDS Relief program; Significance of the health program to AIDS patients.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics